RAMAT GAN, Israel--(BUSINESS WIRE)--Obecure announced today that the last patient to be enrolled in the company’s Phase II clinical trial for obesity has completed treatment. The double-blinded, placebo-controlled, dose-ranging study enrolled 281 patients with a BMI ranging from 30-40 at 20 clinical centers across the U.S. Subjects were randomized into one of four treatment arms comparing placebo with 16 mg., 32 mg., and 48 mg. daily doses of the company’s OBE101 drug candidate. Treatment was administered orally, twice daily, for a duration of 12 weeks. The company expects to present top-level results of the trial in the early fall.
